Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1996-02

AUTHORS

Naftaly Meydan, Tom Grunberger, Harjit Dadi, Michal Shahar, Enrico Arpaia, Zvi Lapidot, J. Steven Leeder, Melvin Freedman, Amos Cohen, Aviv Gazit, Alexander Levitzki, Chaim M. Roifman

ABSTRACT

ACUTE lymphoblastic leukaemia (ALL) is the most common cancer of childhood. Despite the progress achieved in its treatment, 20% of cases relapse and no longer respond to chemotherapy. The most common phenotype of ALL cells share surface antigens with very early precursors of B cells and are therefore believed to originate from this lineage1,3Characterization of the growth requirement of ALL cells indicated that they were dependent on various cytokines, suggesting paracrine and/or autocrine growth regulation4–6. Because many cytokines induce tyrosine phosphorylation in lymphoid progenitor cells, and constitutive tyrosine phosphorylation is commonly observed in B-lineage leukaemias7,8, attempts have been made to develop protein tyrosine kinase (PTK) blockers of leukaemia cell growth9,10. Here we show that leukaemic cells from patients in relapse have con-stitutively activated Jak-2 PTK. Inhibition of Jak-2 activity by a specific tyrosine kinase blocker, AG-490, selectively blocks leukaemic cell growthin vitro and in vivo by inducing programmed cell death, with no deleterious effect on normal haematopoiesis. More... »

PAGES

645-648

Journal

TITLE

Nature

ISSUE

6566

VOLUME

379

Related Patents

  • Pyridin-2(1 H)-One Derivatives As Jak Inhibitors
  • Orally Bioavailable Caffeic Acid Related Anticancer Drugs
  • Heterocyclic-Substituted Pyrrolopyridines And Pyrrolopyrimidines As Jak Inhibitors
  • Method For Inhibiting Eukaryotic Protein Kinases
  • Pyrimidine-2-Amine Compounds And Their Use As Inhibitors Of Jak Kinases
  • Azaindole Derivatives As Tyrosine Kinase Inhibitors
  • Inhibitors Of Proliferation And Activation Of Signal Transducer And Activators Of Transcription (Stats)
  • Compositions For Treatment Of Acute Lymphoblastic Leukemia And Methods Of Use Thereof
  • Inhibitors Of Proliferation And Activation Of Signal Transducer And Activator Of Transcription (Stats)
  • Heterocycle Comprising Tyrosine Kinase Inhibitors
  • Azetidinyl Phenyl, Pyridyl Or Pyrazinyl Carboxamide Derivatives As Jak Inhibitors
  • Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors
  • Processes Of Preparing A Jak1 Inhibitor And New Forms Thereto
  • Bipyrazole Derivatives As Jak Inhibitors
  • 1-(9h-Carbazol-4-Yloxy)Propan-2-Ol Derivatives Such As 1-(9h-Carbazol-4-Yloxy)-3-[(2,4-Dimethoxybenzyl)-Amino]Propan-2-Ol, Used As Phosphorylated Signal Transducers And Activators Of Transcription (Pstat3) And B-Cell Difeerentiation Factor Antagonists, For Treating Inflammatory Diseases And Cancer
  • Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors
  • Treatment Of Pemphigus
  • Low Dose Combination Therapy For Treatment Of Myeloproliferative Neoplasms
  • Tricyclic Fused Thiophene Derivatives As Jak Inhibitors
  • Heterocyclic Derivatives Of Pyrazol-4-Yl-Pyrrolo[2,3-D]Pyrimidines As Janus Kinase Inhibitors
  • Azetidinyl Phenyl, Pyridyl Or Pyrazinyl Carboxamide Derivatives As Jak Inhibitors
  • Administering Tyrphostin Janus-Associated Kinase (Jak) Inhibitor
  • Pyrazole Derivatives As Inhibitors Of Stat3
  • Piperidin-4-Yl Azetidine Derivatives As Jak1 Inhibitors
  • Piperidinylcyclobutyl Substituted Pyrrolopyridine And Pyrrolopyrimidine Derivatives As Jak Inhibitors
  • Processes Of Preparing A Jak1 Inhibitor And New Forms Thereto
  • Treatment Of Chronic Neutrophilic Leukemia (Cnl) And Atypical Chronic Myeloid Leukemia (Acml) By Inhibitors Of Jak1
  • Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
  • Cyclohexyl Azetidine Derivatives As Jak Inhibitors
  • Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors
  • Processes And Intermediates For Making A Jak Inhibitor
  • N-(Hetero)Aryl-Pyrrolidine Derivatives Of Pyrazol-4-Yl-Pyrrolo[2,3-D]Pyrimidines And Pyrrol-3-Yl-Pyrrolo[2,3-D]Pyrimidines As Janus Kinase Inhibitors
  • Compounds For Treatment Of Cell Proliferative Diseases
  • Cyclobutyl Substituted Pyrrolopyridine And Pyrrolopyrimidine Derivatives As Jak Inhibitors
  • Method For Inhibiting Eukaryotic Protein Kinases
  • Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
  • Cyclobutyl Substituted Pyrrolopyridine And Pyrrolopyrimidines Derivatives As Jak Inhibitors
  • Azetidinyl Phenyl, Pyridyl Or Pyrazinyl Carboxamide Derivatives As Jak Inhibitors
  • Tyrosine Kinase Inhibitors As Anti-Kinetoplastid Agents
  • Administering Tyrphostin Janus Associated Kinase Inhibitor
  • N-(Hetero)Aryl-Pyrrolidine Derivatives Of Pyrazol-4-Yl-Pyrrolo[2,3-D]Pyrimidines And Pyrrol-3-Yl-Pyrrolo[2,3-D]Pyrimidines As Janus Kinase Inhibitors
  • Processes And Intermediates For Making A Jak Inhibitor
  • Sustained-Release Dosage Forms Of Ruxolitinib
  • 3-[4-(7h-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1h-Pyrazol-1-Yl]Octane- Or Heptane-Nitrile As Jak Inhibitors
  • Imidazo[1,2-B]Pyridazine And Imidazo[4,5-B]Pyridine Derivatives As Jak Inhibitors
  • Pyrazolyl Substituted Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
  • Substituted Pyrazolo[3,4-D]Pyrimidines As Kinase Inhibitors
  • Piperidin-4-Yl Azetidine Derivatives As Jak1 Inhibitors
  • Pyridin-2(1h)-One Derivatives As Jak Inhibitors
  • Imidazo [1,2-B] Pyridazine And Imidazo [4,5-B] Pyridine Derivatives As Jak Inhibitors
  • Substituted Pyrazolo[3,4-D]Pyrimidines As Kinase Inhibitors
  • Imidazopyridine Derivatives As Jak Inhibitors
  • Bipyrazole Derivatives As Jak Inhibitors
  • Piperidin-4-Yl Azetidine Derivatives As Jak1 Inhibitors
  • Compounds For Treatment Of Cell Proliferative Diseases
  • Methods Of Predicting Responsiveness To Chemotherapeutic Agents And Selecting Treatments
  • Bipyrazole Derivatives As Jak Inhibitors
  • Salts And Solid Form Of A Btk Inhibitor
  • Contacting Activated T Cell Sample With Test Compound, Determining Amounts Of Stat4 Protein And Stat6 Protein Present, Comparing Amounts To Those Present In Corresponding Control Sample That Has Not Been Contacted With Test Compound
  • Sustained-Release Dosage Forms Of Ruxolitinib
  • Sustained Release Dosage Forms For A Jak1 Inhibitor
  • Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
  • Inhibition Of Stat3 Signal Transduction For Human Cancer Therapy
  • Topical Formulation For A Jak Inhibitor
  • Methods For Inhibiting Stat3 Signaling In Immune Cells
  • Tricyclic Fused Thiophene Derivatives As Jak Inhibitors
  • Tyrphostin-Like Compounds That Display A Significant Potency As Kinase Inhibitors, Cause The Downregulation Of C-Myc Proto-Oncogene And Inhibit The Growth And Survival Of Cancerous Cell Lines; Antiproliferative Agents
  • Azetidinyl Phenyl, Pyridyl Or Pyrazinyl Carboxamide Derivatives As Jak Inhibitors
  • Salts And Solid Form Of A Btk Inhibitor
  • Death-Associated Protein Kinases, Inhibitors And Activators Thereof For Use In Pharmaceutical Compositions And In Predictive Medicine
  • Sustained Release Dosage Forms For A Jak1 Inhibitor
  • Pyrazole Derivatives As Inhibitors Of Stat3
  • Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
  • Piperidin-4-Yl Azetidine Derivatives As Jak1 Inhibitors
  • 3-[4-(7h-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1h-Pyrazol-1-Yl]Octane—Or Heptane-Nitrile As Jak Inhibitors
  • Trypanosome Microsome System And Uses Thereof
  • Substituted Pyrazolo[1,5-A]Pyridines As Jak Inhibitors
  • 3-[4-(7h-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1h-Pyrazol-1-Yl]Octane- Or Heptane-Nitrile As Jak Inhibitors
  • Metabolites Of The Janus Kinase Inhibitor (R)-3-(4-(7h-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1h-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
  • Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
  • Pyridin-2(1h)-One Derivatives Useful As Medicaments For The Treatment Of Myeloproliferative Disorders, Transplant Rejection, Immune-Mediated And Inflammatory Diseases
  • Inhibition Of Stat3 Signal Transduction For Human Cancer Therapy
  • Tricyclic Fused Thiophene Derivatives As Jak Inhibitors
  • Low Dose Combination Therapy For Treatment Of Myeloproliferative Neoplasms
  • Treatment Of Hidradenitis Suppurativa Using Jak Inhibitors
  • Piperidin-4-Yl Azetidine Derivatives As Jak1 Inhibitors
  • Topical Formulation For A Jak Inhibitor
  • Pyrazole Derivatives As Jak Inhibitors
  • Tricyclic Fused Thiophene Derivatives As Jak Inhibitors
  • Treatment Of Pemphigus
  • Sustained Release Dosage Forms For A Jak1 Inhibitor
  • Bipyrazole Derivatives As Jak Inhibitors
  • Processes And Intermediates For Making A Jak Inhibitor
  • Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
  • Compounds For Treatment Of Cell Proliferative Diseases
  • Sustained-Release Dosage Forms Of Ruxolitinib
  • Processes And Intermediates For Making A Jak Inhibitor
  • Inhibition Of Stat3 Signal Transduction For Human Cancer Therapy
  • Adding A Lichen Derivived Organic Compound Which Inhibits Sporulation Of Streptomyces To A Sample Or Organism To Inhibit Protein Kinases
  • Caffeic Acid Derivatives And Uses Thereof
  • Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors
  • Sustained-Release Dosage Forms Of Ruxolitinib
  • Method And Composition For Identifying Inhibitors Of Eukaryotic Cell Processes
  • Adding A Lichen Derivived Organic Compound Which Inhibits Sporulation Of Streptomyces To A Sample Or Organism To Inhibit Protein Kinases
  • Pyridin-2 (1h) -One Derivatives Useful As Medicaments For The Treatment Of Myeloproliferative Disorders, Transplant Rejection, Immune-Mediated And Inflammatory Diseases
  • Tricyclic Fused Thiophene Derivatives As Jak Inhibitors
  • Tyrosine Kinase Inhibitors As Anti-Kinetoplastid Agents
  • Metabolites Of The Janus Kinase Inhibitor (R)-3-(4-(7h-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1h-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile
  • Azetidinyl Phenyl, Pyridyl Or Pyrazinyl Carboxamide Derivatives As Jak Inhibitors
  • Inhibition Of Stat3 Signal Transduction For Human Cancer Therapy
  • Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase
  • Pyrimidine-2-Amine Compounds And Their Use As Inhibitors Of Jak Kinases
  • Processes And Intermediates For Making A Jak Inhibitor
  • Processes And Intermediates For Making A Jak Inhibitor
  • Compounds For Treatment Of Cell Proliferative Diseases
  • Processes And Intermediates For Making A Jak Inhibitor
  • Inhibition Of Stat3 Signal Transduction For Human Cancer Therapy
  • Caffeic Acid Derivatives And Uses Thereof
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/379645a0

    DOI

    http://dx.doi.org/10.1038/379645a0

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1027170927

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/8628398


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Biological Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Biochemistry and Cell Biology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "B-Lymphocytes", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cell Division", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Enzyme Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Janus Kinase 2", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mice", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mice, SCID", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasm Transplantation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Nitriles", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Protein-Tyrosine Kinases", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Proto-Oncogene Proteins", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Structure-Activity Relationship", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tumor Cells, Cultured", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tyrphostins", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Divisions of Immunology/Allergy, Haematology and Pharmacology, The Hospital for Sick Children, and the Department of Pediatrics, University of Toronto, M5G 1X8, Toronto, Canada", 
              "id": "http://www.grid.ac/institutes/grid.17063.33", 
              "name": [
                "Divisions of Immunology/Allergy, Haematology and Pharmacology, The Hospital for Sick Children, and the Department of Pediatrics, University of Toronto, M5G 1X8, Toronto, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Meydan", 
            "givenName": "Naftaly", 
            "id": "sg:person.01311213672.33", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01311213672.33"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Divisions of Immunology/Allergy, Haematology and Pharmacology, The Hospital for Sick Children, and the Department of Pediatrics, University of Toronto, M5G 1X8, Toronto, Canada", 
              "id": "http://www.grid.ac/institutes/grid.17063.33", 
              "name": [
                "Divisions of Immunology/Allergy, Haematology and Pharmacology, The Hospital for Sick Children, and the Department of Pediatrics, University of Toronto, M5G 1X8, Toronto, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Grunberger", 
            "givenName": "Tom", 
            "id": "sg:person.014717207674.23", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014717207674.23"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Divisions of Immunology/Allergy, Haematology and Pharmacology, The Hospital for Sick Children, and the Department of Pediatrics, University of Toronto, M5G 1X8, Toronto, Canada", 
              "id": "http://www.grid.ac/institutes/grid.17063.33", 
              "name": [
                "Divisions of Immunology/Allergy, Haematology and Pharmacology, The Hospital for Sick Children, and the Department of Pediatrics, University of Toronto, M5G 1X8, Toronto, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Dadi", 
            "givenName": "Harjit", 
            "id": "sg:person.0723716074.44", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723716074.44"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Divisions of Immunology/Allergy, Haematology and Pharmacology, The Hospital for Sick Children, and the Department of Pediatrics, University of Toronto, M5G 1X8, Toronto, Canada", 
              "id": "http://www.grid.ac/institutes/grid.17063.33", 
              "name": [
                "Divisions of Immunology/Allergy, Haematology and Pharmacology, The Hospital for Sick Children, and the Department of Pediatrics, University of Toronto, M5G 1X8, Toronto, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Shahar", 
            "givenName": "Michal", 
            "id": "sg:person.0655602674.66", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655602674.66"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Divisions of Immunology/Allergy, Haematology and Pharmacology, The Hospital for Sick Children, and the Department of Pediatrics, University of Toronto, M5G 1X8, Toronto, Canada", 
              "id": "http://www.grid.ac/institutes/grid.17063.33", 
              "name": [
                "Divisions of Immunology/Allergy, Haematology and Pharmacology, The Hospital for Sick Children, and the Department of Pediatrics, University of Toronto, M5G 1X8, Toronto, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Arpaia", 
            "givenName": "Enrico", 
            "id": "sg:person.0607467474.28", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607467474.28"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Immunology, The Weizmann Institute, Rehovot, Israel", 
              "id": "http://www.grid.ac/institutes/grid.13992.30", 
              "name": [
                "Department of Immunology, The Weizmann Institute, Rehovot, Israel"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lapidot", 
            "givenName": "Zvi", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Divisions of Immunology/Allergy, Haematology and Pharmacology, The Hospital for Sick Children, and the Department of Pediatrics, University of Toronto, M5G 1X8, Toronto, Canada", 
              "id": "http://www.grid.ac/institutes/grid.17063.33", 
              "name": [
                "Divisions of Immunology/Allergy, Haematology and Pharmacology, The Hospital for Sick Children, and the Department of Pediatrics, University of Toronto, M5G 1X8, Toronto, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Leeder", 
            "givenName": "J. Steven", 
            "id": "sg:person.0660571174.73", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660571174.73"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Divisions of Immunology/Allergy, Haematology and Pharmacology, The Hospital for Sick Children, and the Department of Pediatrics, University of Toronto, M5G 1X8, Toronto, Canada", 
              "id": "http://www.grid.ac/institutes/grid.17063.33", 
              "name": [
                "Divisions of Immunology/Allergy, Haematology and Pharmacology, The Hospital for Sick Children, and the Department of Pediatrics, University of Toronto, M5G 1X8, Toronto, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Freedman", 
            "givenName": "Melvin", 
            "id": "sg:person.012171503002.30", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012171503002.30"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Divisions of Immunology/Allergy, Haematology and Pharmacology, The Hospital for Sick Children, and the Department of Pediatrics, University of Toronto, M5G 1X8, Toronto, Canada", 
              "id": "http://www.grid.ac/institutes/grid.17063.33", 
              "name": [
                "Divisions of Immunology/Allergy, Haematology and Pharmacology, The Hospital for Sick Children, and the Department of Pediatrics, University of Toronto, M5G 1X8, Toronto, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Cohen", 
            "givenName": "Amos", 
            "id": "sg:person.0646451442.97", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646451442.97"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Biological Chemistry, Institute of Life Sciences, The Hebrew University, Jerusalem, Israel", 
              "id": "http://www.grid.ac/institutes/grid.9619.7", 
              "name": [
                "Department of Biological Chemistry, Institute of Life Sciences, The Hebrew University, Jerusalem, Israel"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Gazit", 
            "givenName": "Aviv", 
            "id": "sg:person.01132407167.25", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01132407167.25"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Biological Chemistry, Institute of Life Sciences, The Hebrew University, Jerusalem, Israel", 
              "id": "http://www.grid.ac/institutes/grid.9619.7", 
              "name": [
                "Department of Biological Chemistry, Institute of Life Sciences, The Hebrew University, Jerusalem, Israel"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Levitzki", 
            "givenName": "Alexander", 
            "id": "sg:person.01320127617.91", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320127617.91"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Divisions of Immunology/Allergy, Haematology and Pharmacology, The Hospital for Sick Children, and the Department of Pediatrics, University of Toronto, M5G 1X8, Toronto, Canada", 
              "id": "http://www.grid.ac/institutes/grid.17063.33", 
              "name": [
                "Divisions of Immunology/Allergy, Haematology and Pharmacology, The Hospital for Sick Children, and the Department of Pediatrics, University of Toronto, M5G 1X8, Toronto, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Roifman", 
            "givenName": "Chaim M.", 
            "id": "sg:person.013262675417.68", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013262675417.68"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/370151a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010238294", 
              "https://doi.org/10.1038/370151a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/343076a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051945097", 
              "https://doi.org/10.1038/343076a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/370153a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036067090", 
              "https://doi.org/10.1038/370153a0"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1996-02", 
        "datePublishedReg": "1996-02-01", 
        "description": "ACUTE lymphoblastic leukaemia (ALL) is the most common cancer of childhood. Despite the progress achieved in its treatment, 20% of cases relapse and no longer respond to chemotherapy. The most common phenotype of ALL cells share surface antigens with very early precursors of B cells and are therefore believed to originate from this lineage1,3Characterization of the growth requirement of ALL cells indicated that they were dependent on various cytokines, suggesting paracrine and/or autocrine growth regulation4\u20136. Because many cytokines induce tyrosine phosphorylation in lymphoid progenitor cells, and constitutive tyrosine phosphorylation is commonly observed in B-lineage leukaemias7,8, attempts have been made to develop protein tyrosine kinase (PTK) blockers of leukaemia cell growth9,10. Here we show that leukaemic cells from patients in relapse have con-stitutively activated Jak-2 PTK. Inhibition of Jak-2 activity by a specific tyrosine kinase blocker, AG-490, selectively blocks leukaemic cell growthin vitro and in vivo by inducing programmed cell death, with no deleterious effect on normal haematopoiesis.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/379645a0", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1018957", 
            "issn": [
              "0028-0836", 
              "1476-4687"
            ], 
            "name": "Nature", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "6566", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "379"
          }
        ], 
        "keywords": [
          "acute lymphoblastic leukemia", 
          "lymphoblastic leukemia", 
          "tyrosine kinase blockers", 
          "kinase blockers", 
          "JAK-2 inhibitor", 
          "lymphoid progenitor cells", 
          "common cancer", 
          "tyrosine phosphorylation", 
          "leukaemic cells", 
          "B cells", 
          "protein tyrosine kinase blockers", 
          "B-lineage", 
          "normal haematopoiesis", 
          "progenitor cells", 
          "leukemia cells", 
          "AG-490", 
          "common phenotype", 
          "cytokines", 
          "blockers", 
          "leukemia", 
          "deleterious effects", 
          "cell death", 
          "cells", 
          "inhibition", 
          "early precursors", 
          "growth requirements", 
          "chemotherapy", 
          "relapse", 
          "patients", 
          "cancer", 
          "phosphorylation", 
          "paracrine", 
          "death", 
          "childhood", 
          "treatment", 
          "haematopoiesis", 
          "vivo", 
          "inhibitors", 
          "growthin", 
          "phenotype", 
          "PTK", 
          "cases", 
          "activity", 
          "cons", 
          "effect", 
          "precursors", 
          "progress", 
          "attempt", 
          "requirements", 
          "surface"
        ], 
        "name": "Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor", 
        "pagination": "645-648", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1027170927"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/379645a0"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "8628398"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/379645a0", 
          "https://app.dimensions.ai/details/publication/pub.1027170927"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-09-02T15:47", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_268.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/379645a0"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/379645a0'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/379645a0'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/379645a0'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/379645a0'


     

    This table displays all metadata directly associated to this object as RDF triples.

    281 TRIPLES      21 PREDICATES      98 URIs      85 LITERALS      24 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/379645a0 schema:about N0a8fe8d59d8d426eb7dda5d96607f1a0
    2 N113d41c5fa9746ffb33cc47baa3026f2
    3 N13ea3146759a447085cda6c176e92924
    4 N2ccbd7579278402a8feaf0dade809370
    5 N3fd2bb0622da4435867af5bdcbb0484b
    6 N43475f0fd6bf4fbeaf42211daa927741
    7 N544fa24efc3c42a5826dfb519023dc57
    8 N72261edb39a44880baa44c5984edc419
    9 N8094bb26e70f4a2e94721f7437ad7fec
    10 N81f2d1be83f44ee086c06e17fd0eed9d
    11 N97ef684451dd42c59eb8db09694a6a22
    12 N9a291cf94ab84c40945f9105b224e782
    13 Nc8c737f1fb244f04b3cbb06f7f6ded09
    14 Ne50c4a851a8948e6bc811cd064f3e695
    15 Necc277d288dc4ba1b8f7006ad595038b
    16 Necc5f67f82094af39a9b8496a2780cd2
    17 Nef647f314bcb42adb9225fe36a0e3a5e
    18 anzsrc-for:06
    19 anzsrc-for:0601
    20 anzsrc-for:11
    21 anzsrc-for:1112
    22 schema:author N5a26c289f5b44ce4b8d80b8fec7d1aac
    23 schema:citation sg:pub.10.1038/343076a0
    24 sg:pub.10.1038/370151a0
    25 sg:pub.10.1038/370153a0
    26 schema:datePublished 1996-02
    27 schema:datePublishedReg 1996-02-01
    28 schema:description ACUTE lymphoblastic leukaemia (ALL) is the most common cancer of childhood. Despite the progress achieved in its treatment, 20% of cases relapse and no longer respond to chemotherapy. The most common phenotype of ALL cells share surface antigens with very early precursors of B cells and are therefore believed to originate from this lineage1,3Characterization of the growth requirement of ALL cells indicated that they were dependent on various cytokines, suggesting paracrine and/or autocrine growth regulation4–6. Because many cytokines induce tyrosine phosphorylation in lymphoid progenitor cells, and constitutive tyrosine phosphorylation is commonly observed in B-lineage leukaemias7,8, attempts have been made to develop protein tyrosine kinase (PTK) blockers of leukaemia cell growth9,10. Here we show that leukaemic cells from patients in relapse have con-stitutively activated Jak-2 PTK. Inhibition of Jak-2 activity by a specific tyrosine kinase blocker, AG-490, selectively blocks leukaemic cell growthin vitro and in vivo by inducing programmed cell death, with no deleterious effect on normal haematopoiesis.
    29 schema:genre article
    30 schema:isAccessibleForFree false
    31 schema:isPartOf N4eaebdb228a74ed98185c026220b346b
    32 N9b48c0d190b54011a289fd20996a58e5
    33 sg:journal.1018957
    34 schema:keywords AG-490
    35 B cells
    36 B-lineage
    37 JAK-2 inhibitor
    38 PTK
    39 activity
    40 acute lymphoblastic leukemia
    41 attempt
    42 blockers
    43 cancer
    44 cases
    45 cell death
    46 cells
    47 chemotherapy
    48 childhood
    49 common cancer
    50 common phenotype
    51 cons
    52 cytokines
    53 death
    54 deleterious effects
    55 early precursors
    56 effect
    57 growth requirements
    58 growthin
    59 haematopoiesis
    60 inhibition
    61 inhibitors
    62 kinase blockers
    63 leukaemic cells
    64 leukemia
    65 leukemia cells
    66 lymphoblastic leukemia
    67 lymphoid progenitor cells
    68 normal haematopoiesis
    69 paracrine
    70 patients
    71 phenotype
    72 phosphorylation
    73 precursors
    74 progenitor cells
    75 progress
    76 protein tyrosine kinase blockers
    77 relapse
    78 requirements
    79 surface
    80 treatment
    81 tyrosine kinase blockers
    82 tyrosine phosphorylation
    83 vivo
    84 schema:name Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor
    85 schema:pagination 645-648
    86 schema:productId N613bb0fd0c5649c18298d7fdb22fc923
    87 N8cc7df2a76c84b3b872b850d2ec1bf60
    88 Na27b0af0cbe54c98a65e325620f8c837
    89 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027170927
    90 https://doi.org/10.1038/379645a0
    91 schema:sdDatePublished 2022-09-02T15:47
    92 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    93 schema:sdPublisher N8b4ec48d2b2842ba9223ccdde853cba7
    94 schema:url https://doi.org/10.1038/379645a0
    95 sgo:license sg:explorer/license/
    96 sgo:sdDataset articles
    97 rdf:type schema:ScholarlyArticle
    98 N0a8fe8d59d8d426eb7dda5d96607f1a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    99 schema:name Proto-Oncogene Proteins
    100 rdf:type schema:DefinedTerm
    101 N0be2ed96e1834dea9d270801ebd6f693 rdf:first sg:person.0646451442.97
    102 rdf:rest N160bf34f230d403b9059c0eaf4ddda92
    103 N113d41c5fa9746ffb33cc47baa3026f2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    104 schema:name Mice
    105 rdf:type schema:DefinedTerm
    106 N13ea3146759a447085cda6c176e92924 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    107 schema:name Enzyme Inhibitors
    108 rdf:type schema:DefinedTerm
    109 N160bf34f230d403b9059c0eaf4ddda92 rdf:first sg:person.01132407167.25
    110 rdf:rest Neb054041e7974db9ab00f54b00bd83e3
    111 N18f5169e5e084c518732111508e3358d rdf:first sg:person.0723716074.44
    112 rdf:rest N34f03a69028e4b24ab4bebd9c9c4e049
    113 N2ccbd7579278402a8feaf0dade809370 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    114 schema:name Mice, SCID
    115 rdf:type schema:DefinedTerm
    116 N34f03a69028e4b24ab4bebd9c9c4e049 rdf:first sg:person.0655602674.66
    117 rdf:rest Nbb18f7c5d4af4de7a04dcf8687ac9fe2
    118 N3fd2bb0622da4435867af5bdcbb0484b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    119 schema:name Janus Kinase 2
    120 rdf:type schema:DefinedTerm
    121 N43475f0fd6bf4fbeaf42211daa927741 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    122 schema:name Humans
    123 rdf:type schema:DefinedTerm
    124 N4eaebdb228a74ed98185c026220b346b schema:issueNumber 6566
    125 rdf:type schema:PublicationIssue
    126 N544fa24efc3c42a5826dfb519023dc57 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    127 schema:name Protein-Tyrosine Kinases
    128 rdf:type schema:DefinedTerm
    129 N5a26c289f5b44ce4b8d80b8fec7d1aac rdf:first sg:person.01311213672.33
    130 rdf:rest Nc1cb92b2cea447d483a5af73ba6f5486
    131 N5cc8142ca57a47839cd1be1a6e96981f rdf:first Na78772691293466995495e4a9710fe21
    132 rdf:rest Na41de9d27c5540ec9d186042e1ba8f1b
    133 N613bb0fd0c5649c18298d7fdb22fc923 schema:name pubmed_id
    134 schema:value 8628398
    135 rdf:type schema:PropertyValue
    136 N72261edb39a44880baa44c5984edc419 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    137 schema:name Antineoplastic Agents
    138 rdf:type schema:DefinedTerm
    139 N8094bb26e70f4a2e94721f7437ad7fec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    140 schema:name Structure-Activity Relationship
    141 rdf:type schema:DefinedTerm
    142 N81f2d1be83f44ee086c06e17fd0eed9d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    143 schema:name Neoplasm Transplantation
    144 rdf:type schema:DefinedTerm
    145 N8b4ec48d2b2842ba9223ccdde853cba7 schema:name Springer Nature - SN SciGraph project
    146 rdf:type schema:Organization
    147 N8cc7df2a76c84b3b872b850d2ec1bf60 schema:name doi
    148 schema:value 10.1038/379645a0
    149 rdf:type schema:PropertyValue
    150 N97ef684451dd42c59eb8db09694a6a22 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    151 schema:name Tyrphostins
    152 rdf:type schema:DefinedTerm
    153 N97fb0bcc46b44a3f9d7612a6aec141fb rdf:first sg:person.013262675417.68
    154 rdf:rest rdf:nil
    155 N9a291cf94ab84c40945f9105b224e782 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    156 schema:name Animals
    157 rdf:type schema:DefinedTerm
    158 N9b48c0d190b54011a289fd20996a58e5 schema:volumeNumber 379
    159 rdf:type schema:PublicationVolume
    160 Na27b0af0cbe54c98a65e325620f8c837 schema:name dimensions_id
    161 schema:value pub.1027170927
    162 rdf:type schema:PropertyValue
    163 Na41de9d27c5540ec9d186042e1ba8f1b rdf:first sg:person.0660571174.73
    164 rdf:rest Nd6303cb43c784730a568131c92fd407d
    165 Na78772691293466995495e4a9710fe21 schema:affiliation grid-institutes:grid.13992.30
    166 schema:familyName Lapidot
    167 schema:givenName Zvi
    168 rdf:type schema:Person
    169 Nbb18f7c5d4af4de7a04dcf8687ac9fe2 rdf:first sg:person.0607467474.28
    170 rdf:rest N5cc8142ca57a47839cd1be1a6e96981f
    171 Nc1cb92b2cea447d483a5af73ba6f5486 rdf:first sg:person.014717207674.23
    172 rdf:rest N18f5169e5e084c518732111508e3358d
    173 Nc8c737f1fb244f04b3cbb06f7f6ded09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    174 schema:name B-Lymphocytes
    175 rdf:type schema:DefinedTerm
    176 Nd6303cb43c784730a568131c92fd407d rdf:first sg:person.012171503002.30
    177 rdf:rest N0be2ed96e1834dea9d270801ebd6f693
    178 Ne50c4a851a8948e6bc811cd064f3e695 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    179 schema:name Tumor Cells, Cultured
    180 rdf:type schema:DefinedTerm
    181 Neb054041e7974db9ab00f54b00bd83e3 rdf:first sg:person.01320127617.91
    182 rdf:rest N97fb0bcc46b44a3f9d7612a6aec141fb
    183 Necc277d288dc4ba1b8f7006ad595038b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    184 schema:name Precursor Cell Lymphoblastic Leukemia-Lymphoma
    185 rdf:type schema:DefinedTerm
    186 Necc5f67f82094af39a9b8496a2780cd2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    187 schema:name Cell Division
    188 rdf:type schema:DefinedTerm
    189 Nef647f314bcb42adb9225fe36a0e3a5e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    190 schema:name Nitriles
    191 rdf:type schema:DefinedTerm
    192 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
    193 schema:name Biological Sciences
    194 rdf:type schema:DefinedTerm
    195 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
    196 schema:name Biochemistry and Cell Biology
    197 rdf:type schema:DefinedTerm
    198 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    199 schema:name Medical and Health Sciences
    200 rdf:type schema:DefinedTerm
    201 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    202 schema:name Oncology and Carcinogenesis
    203 rdf:type schema:DefinedTerm
    204 sg:journal.1018957 schema:issn 0028-0836
    205 1476-4687
    206 schema:name Nature
    207 schema:publisher Springer Nature
    208 rdf:type schema:Periodical
    209 sg:person.01132407167.25 schema:affiliation grid-institutes:grid.9619.7
    210 schema:familyName Gazit
    211 schema:givenName Aviv
    212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01132407167.25
    213 rdf:type schema:Person
    214 sg:person.012171503002.30 schema:affiliation grid-institutes:grid.17063.33
    215 schema:familyName Freedman
    216 schema:givenName Melvin
    217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012171503002.30
    218 rdf:type schema:Person
    219 sg:person.01311213672.33 schema:affiliation grid-institutes:grid.17063.33
    220 schema:familyName Meydan
    221 schema:givenName Naftaly
    222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01311213672.33
    223 rdf:type schema:Person
    224 sg:person.01320127617.91 schema:affiliation grid-institutes:grid.9619.7
    225 schema:familyName Levitzki
    226 schema:givenName Alexander
    227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320127617.91
    228 rdf:type schema:Person
    229 sg:person.013262675417.68 schema:affiliation grid-institutes:grid.17063.33
    230 schema:familyName Roifman
    231 schema:givenName Chaim M.
    232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013262675417.68
    233 rdf:type schema:Person
    234 sg:person.014717207674.23 schema:affiliation grid-institutes:grid.17063.33
    235 schema:familyName Grunberger
    236 schema:givenName Tom
    237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014717207674.23
    238 rdf:type schema:Person
    239 sg:person.0607467474.28 schema:affiliation grid-institutes:grid.17063.33
    240 schema:familyName Arpaia
    241 schema:givenName Enrico
    242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607467474.28
    243 rdf:type schema:Person
    244 sg:person.0646451442.97 schema:affiliation grid-institutes:grid.17063.33
    245 schema:familyName Cohen
    246 schema:givenName Amos
    247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646451442.97
    248 rdf:type schema:Person
    249 sg:person.0655602674.66 schema:affiliation grid-institutes:grid.17063.33
    250 schema:familyName Shahar
    251 schema:givenName Michal
    252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655602674.66
    253 rdf:type schema:Person
    254 sg:person.0660571174.73 schema:affiliation grid-institutes:grid.17063.33
    255 schema:familyName Leeder
    256 schema:givenName J. Steven
    257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660571174.73
    258 rdf:type schema:Person
    259 sg:person.0723716074.44 schema:affiliation grid-institutes:grid.17063.33
    260 schema:familyName Dadi
    261 schema:givenName Harjit
    262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723716074.44
    263 rdf:type schema:Person
    264 sg:pub.10.1038/343076a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051945097
    265 https://doi.org/10.1038/343076a0
    266 rdf:type schema:CreativeWork
    267 sg:pub.10.1038/370151a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010238294
    268 https://doi.org/10.1038/370151a0
    269 rdf:type schema:CreativeWork
    270 sg:pub.10.1038/370153a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036067090
    271 https://doi.org/10.1038/370153a0
    272 rdf:type schema:CreativeWork
    273 grid-institutes:grid.13992.30 schema:alternateName Department of Immunology, The Weizmann Institute, Rehovot, Israel
    274 schema:name Department of Immunology, The Weizmann Institute, Rehovot, Israel
    275 rdf:type schema:Organization
    276 grid-institutes:grid.17063.33 schema:alternateName Divisions of Immunology/Allergy, Haematology and Pharmacology, The Hospital for Sick Children, and the Department of Pediatrics, University of Toronto, M5G 1X8, Toronto, Canada
    277 schema:name Divisions of Immunology/Allergy, Haematology and Pharmacology, The Hospital for Sick Children, and the Department of Pediatrics, University of Toronto, M5G 1X8, Toronto, Canada
    278 rdf:type schema:Organization
    279 grid-institutes:grid.9619.7 schema:alternateName Department of Biological Chemistry, Institute of Life Sciences, The Hebrew University, Jerusalem, Israel
    280 schema:name Department of Biological Chemistry, Institute of Life Sciences, The Hebrew University, Jerusalem, Israel
    281 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...